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• The androgen receptor (AR) pathway is a major 
contributor to prostate cancer (PC) & tumor 
growth. Therapeutic strategies & drugs attempt 
to disrupt this pathway to slow or stop tumor 
growth. Typically, an AR antagonist is used, 
which binds to the AR as an inhibitor. 
• Targeted protein degradation is a rapidly 
growing area in drug design & has been 
suggested as another treatment strategy for 
cancers.1 One method of targeted protein 
degradation is hydrophobic tagging.2
• One strategy uses heterobifunctional molecules 
known as PROteolysis TArgeting Chimeras 
(PROTACs). These consist of a ligand for a 
protein of interest (POI) on one end, connected 
by a linker to a group known to induce 
degradation, also known as a degron.1
• Our research aims: treat PC cells with 
PROTACs to selectively degrade the AR by 
attaching various hydrophobic moieties, 
measuring their relative effectiveness as 
degrons. If these are effective degrons, a 
chemical library of degrons can be established.
Synthesis
• Each peptoid was synthesized using a solid-
phase peptoid synthesis procedure3, using 
Rink-amide Resin.
• After an unsuccessful BOC-anhydride 
protection reaction for some of the bulkier 
compounds (C1-6A, C1-6B) 4-
dimethylaminopyridine (DMAP) was used as a 
catalyst.
• Preparative high-performance liquid 
chromatography (H2O/ACN) 
• The AR antagonist was synthesized and 
purified through column chromatography4.
Characterization
• Analytical high-performance liquid 
chromatography was used to confirm the 
presence of the synthesized compounds. 
(H2O/ACN)
• Mass spectrometry was also used to confirm 
that the proper compounds had been 
synthesized by finding the weight of the 
molecular ion.
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Compound Design
Figure 4. C1-1B; Histidine Peptoid Moiety
Figure 5. C1-6A; Adamantyl Peptoid Moiety
Figure 6. C1-6B; Naphthalene Peptoid Moiety
Figure 2. Generic structure of the AR PROTAC
• Link the AR antagonist and hydrophobic 
moieties
• More batches of PROTACs are being 
synthesized and purified
• Various linkers can be tested.5
• LNCaP, an AR-positive prostate cancer cell line, 
will be used to test these compounds in vitro
• If testing is successful, the Ubiquitin-
Proteasome system can be analyzed to 
determine the mechanism of degradation
• NMR spectra will be obtained.
• PROTACs and hydrophobic tagging have 
shown separate successes in the past.
• These hydrophobic moieties and the AR 
antagonist have been successfully synthesized.
• The compounds are relatively small, meaning 
they could be druggable.
• If these compounds are effective at degrading 
the androgen receptor, this can then be applied 
to other cancers and diseases that rely on a 
protein-mediated pathway.
• If these drug treatments are successful, a 
chemical library can be established
Figure 1. PROTAC mode of action, using an E3 ligase.6
Figure 3. C1-1A; Diphenylethylene Peptoid Moiety
